Black Diamond Therapeutics (BDTX) Research & Development (2019 - 2021)
Historic Research & Development for Black Diamond Therapeutics (BDTX) over the last 3 years, with Q4 2021 value amounting to $19.7 million.
- Black Diamond Therapeutics' Research & Development rose 1074.57% to $19.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was $91.8 million, marking a year-over-year increase of 8993.07%. This contributed to the annual value of $96.8 million for FY2021, which is 10085.25% up from last year.
- Black Diamond Therapeutics' Research & Development amounted to $19.7 million in Q4 2021, which was up 1074.57% from $27.6 million recorded in Q3 2021.
- Black Diamond Therapeutics' Research & Development's 5-year high stood at $27.6 million during Q3 2021, with a 5-year trough of $5.6 million in Q3 2019.
- Over the past 3 years, Black Diamond Therapeutics' median Research & Development value was $12.9 million (recorded in 2020), while the average stood at $14.8 million.
- Examining YoY changes over the last 5 years, Black Diamond Therapeutics' Research & Development showed a top increase of 16272.37% in 2021 and a maximum decrease of 1074.57% in 2021.
- Black Diamond Therapeutics' Research & Development (Quarter) stood at $7.5 million in 2019, then surged by 138.02% to $17.8 million in 2020, then grew by 10.75% to $19.7 million in 2021.
- Its Research & Development was $19.7 million in Q4 2021, compared to $27.6 million in Q3 2021 and $26.7 million in Q2 2021.